Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
Completed · Phase 2
Conditions studied: Head and Neck Cancer
In brief
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have unresectable and/or metastatic salivary gland cancer.
Key facts
- Study ID
- NCT00045669
- Run by
- University Health Network, Toronto
- People needed
- 16
- Starts
- 2002-07-01
- Expected to finish
- 2005-01-01
- Last updated by the study team
- 2019-02-15
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
- Evanston Northwestern Health Care - Evanston Hospital — Evanston, Illinois, United States
- Ingalls Memorial Hospital — Harvey, Illinois, United States
- LaGrange Memorial Hospital — LaGrange, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Incorporated — Fort Wayne, Indiana, United States
- CCOP - Northern Indiana CR Consortium — South Bend, Indiana, United States
- Lakeland Medical Center - St. Joseph — Saint Joseph, Michigan, United States
- Siteman Cancer Center — St Louis, Missouri, United States
- University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
- Cancer Care Ontario-Hamilton Regional Cancer Centre — Hamilton, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.